Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Karlheinz Merkle"'
Autor:
Klaus Ruffert, Karlheinz Merkle, Lorenzo Leoni, Michael Herold, Walter Werner, Bruce D. Cheson, Axel Brakhage
Publikováno v:
Oncology Research and Treatment. 36:2-10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d1cf7a0c4d708ce869f8bc493d5e0ac
https://doi.org/10.1159/000346104
https://doi.org/10.1159/000346104
Autor:
Wolfgang Knauf, Marco Montillo, Liana Gercheva, Javier Loscertales, Toshko Lissichkov, Peter S. Klein, Raoul Herbrecht, Ilaria Del Giudice, Lothar Tremmel, Anna Marina Liberati, Martin Becker, Gerhard Postner, Gunnar Juliusson, Karlheinz Merkle, Hans Joerg Fricke, Ali Aldaoud, Françoise Huguet, Stefan Goranov
Publikováno v:
Journal of Clinical Oncology. 27:4378-4384
Purpose This randomized, open-label, parallel-group, multicenter study was designed to compare the efficacy and safety of bendamustine and chlorambucil in previously untreated patients with advanced (Binet stage B or C) chronic lymphocytic leukemia (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60fda8805fdeaf06d2480ed7eb2ef3bc
https://doi.org/10.1200/jco.2008.20.8389
https://doi.org/10.1200/jco.2008.20.8389
Autor:
Marika Rasschaert, Karlheinz Merkle, J. Dyck, Johan Bosmans, Jan Van den Brande, Jan B. Vermorken, Dirk Schrijvers
Publikováno v:
Anti-cancer drugs: an international journal on anti-cancer agents
The present phase I trial was planned to assess the maximum tolerated dose, the dose-limiting toxicity and the pharmacokinetics of bendamustine hydrochloride in a once every 3 weeks schedule, and to recommend a safe dose for future phase II studies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05dc7afec5b6eacb535c0c8ed9a41bce
https://doi.org/10.1097/cad.0b013e3280149eb1
https://doi.org/10.1097/cad.0b013e3280149eb1
Autor:
Jens Teichert, Frank Baumann, Rainer Preiss, Lothar Hennig, Reinhard Sohr, Karlheinz Merkle, Karel Caca
Publikováno v:
Drug Metabolism and Disposition. 33:984-992
The alkylating agent bendamustine is currently in phase III clinical trials for the treatment of hematological malignancies and breast, lung, and gastrointestinal tumors. Renal elimination mainly as the parent compound is thought to be the primary ro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08f6870d675b27f43662c1d457a10d89
https://doi.org/10.1124/dmd.105.003624
https://doi.org/10.1124/dmd.105.003624
Autor:
Walter, Werner, Michael, Herold, Klaus, Ruffert, Karlheinz, Merkle, Axel, Brakhage, Lorenzo, Leoni, Hans, Knoell
Publikováno v:
Onkologie. 36
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::79afbd22f78b64c56afeb14084e7113a
https://pubmed.ncbi.nlm.nih.gov/23445757
https://pubmed.ncbi.nlm.nih.gov/23445757
Autor:
Karlheinz Merkle, Wolfgang Knauf, Ilaria Del Giudice, Javier Loscertales, Martin Becker, Marco Montillo, Stefan Goranov, Gerhard Postner, Gunnar Juliusson, Anna M. Liberati, Toshko Lissitchkov, Peter S. Klein, Hans Joerg Fricke, Liana Gercheva, Ali Aldaoud, Françoise Huguet, Raoul Herbrecht
The efficacy of bendamustine versus chlorambucil in a phase III trial of previously untreated patients with Binet stage B/C chronic lymphocytic leukaemia (CLL) was re-evaluated after a median observation time of 54 months in May 2010. Overall surviva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b3038e7e31a96ead4cb21f4c890d62
http://hdl.handle.net/11573/481318
http://hdl.handle.net/11573/481318
Autor:
Gunnar Juliusson, Françoise Huguet, Hans-Joerg Fricke, Javier Loscertales, Ali Aldaoud, Peter S. Klein, Wolfgang Knauf, Liana Gercheva, Raoul Herbrecht, Toshko Lissitchkov, Anna Marina Liberati, Gerhard Postner, Marco Montillo, Ilaria Del Guidice, Martin Becker, Stefan Goranov, Karlheinz Merkle
Abstract 2449 Introduction: Bendamustine (BEN), either alone or in combination with Rituximab, is increasingly used in the treatment of chronic lymphocytic leukemia (CLL) and various types of low grade Non Hodgkin's Lymphoma (NHL). The approval to tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8020b6b6ef92fe4366b16508cb2ca865
http://hdl.handle.net/11573/482158
http://hdl.handle.net/11573/482158
Autor:
Liana Gercheva, Anna M. Liberati, Françoise Huguet, Hans-Joerg Fricke, Ilaria Del Giudice, Toshko Lissitchkov, Martin Becker, Karlheinz Merkle, Ali Aldaoud, Stefan Goranov, Javier Loscertales, Wolfgang Knauf, Peter S. Klein, Gunnar Juliusson, Marco Montillo, Gerhard Postner, Raoul Herbrecht
Abstract 2367 Poster Board II-344 Introduction: Bendamustine is a purine analog/alkylator hybrid agent with a unique mechanism of action, which has shown good clinical efficacy and acceptable tolerability in various hematological malignancies. Chroni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ed66cb4854ba831393a0f7ef607b9dd
http://hdl.handle.net/11573/482149
http://hdl.handle.net/11573/482149
Autor:
Javier Loscertales, Roul Herbrecht, Gerhard Postner, Stefan Goranov, Klaus Hoeffken, Gunnar Juliusson, Marco Montillo, Martin Becker, Karlheinz Merkle, Toshko Lissitchkov, Liana Gercheva, Robert Foa, Françoise Huguet, Wolfgang Knauf, Ali Aldaoud, Anna M. Liberati
Introduction: Bendamustine is a purine analog/alkylator hybrid agent with a unique mechanism of action, which has shown good clinical efficacy and acceptable tolerability in various hematological malignancies, including Hodgkin’s disease, non-Hodgk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a69ed95b3cdbdb3c5bec9cb828926e7
http://hdl.handle.net/11391/1011137
http://hdl.handle.net/11391/1011137
Autor:
Toshko Lissichkov, Javier Loscertales, Ali Aldaoud, Anna Marina Liberati, Raoul Herbrecht, Karlheinz Merkle, Christian Dittrich, Gunnar Juliusson, Wolfgang Knauf
Publikováno v:
Blood. 110:2043-2043
Introduction: Bendamustine (BEN) is a purine analog / alkylator hybrid agent with a particular mechanisms of action that provides effective treatment for a number of hematologic and non-hematologic malignancies. It is used primarily for chemo-naïve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::895db1daea005b570586d4d76af6c3ec
https://doi.org/10.1182/blood.v110.11.2043.2043
https://doi.org/10.1182/blood.v110.11.2043.2043